Institution · ORASIS Pharmaceuticals (Israel)

Most cited papers from ORASIS Pharmaceuticals (Israel)

ORASIS Pharmaceuticals (Israel)

What are the most cited papers from ORASIS Pharmaceuticals (Israel)?

The most cited paper from ORASIS Pharmaceuticals (Israel) is "Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study" (Shepherd Roee Singer, Frederick J. Angulo, David L. Swerdlow et al., 2021), with 29 citations. Next come "Epidemiology of clinically significant migraine in Israel: a retrospective database study" (7) and "Cancer‐associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study" (7).

Published FieldAccess

Showing 9 of 9 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study Shepherd Roee Singer, Frederick J. Angulo, David L. Swerdlow et al. · EClinicalMedicine Open access	29 Nov 2021	29
2	Epidemiology of clinically significant migraine in Israel: a retrospective database study Alla Shifrin, Eytan Domany, Matanya Tirosh et al. · The Journal of Headache and Pain Open access	3 Feb 2025	7
3	Cancer‐associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study Sarah Sharman Moser, Galia Spectre, Pia Raanani et al. · Research and Practice in Thrombosis and Haemostasis Open access	Apr 2022	7
4	Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial Yuval Ishay, Joel Neutel, Yotam Kolben et al. · Gastro Hep Advances Open access	7 Dec 2023	3
5	Triptan Use and Potential Undertreatment in Migraine: A Retrospective Cohort Study Yael Barer, Moshe Hoshen, Sivan Gazit et al. · Journal of Clinical Medicine Open access	12 Feb 2026	2
6	Novel biophysical skin biomarkers discriminate topical anti‐inflammatory treatments based on their potential for local adverse effects Simon G. Danby, Stephen J. Matcher, Robert A. Byers et al. · JEADV Clinical Practice Open access	9 Sep 2024	2
7	500P Second-line therapies after first-line CDK4/6 inhibitor in endocrine-sensitive or de novo advanced ER+/HER2- breast cancer: ALBANE, a French nationwide study P.H. Cottu, V. Rondeau, R Hamood et al. · ESMO Open Open access	May 2026	0
8	Primary care physicians’ perspectives on managing mild-to-moderate COVID-19 in populations at risk for progression to severe disease: a survey-based study Carmel Kasher, Tal Distelman-Menachem, Avital Bareket‐Samish et al. · BMC Family Practice Open access	21 May 2026	0
9	Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US Kennedy Cook, Nada M. Elbuluk, Roni Adiri et al. · The Journal of Dermatology Open access	6 Apr 2026	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.